Wells Fargo & Company MN raised its stake in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 28.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,335,906 shares of the specialty pharmaceutical company’s stock after acquiring an additional 294,810 shares during the quarter. Wells Fargo & Company MN’s holdings in Antares Pharma were worth $4,328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Advantage Inc. purchased a new position in Antares Pharma during the third quarter valued at $110,000. Alliancebernstein L.P. purchased a new position in shares of Antares Pharma in the second quarter worth about $119,000. Legal & General Group Plc purchased a new position in shares of Antares Pharma in the second quarter worth about $120,000. MML Investors Services LLC lifted its stake in shares of Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 30,000 shares in the last quarter. Finally, First Eagle Investment Management LLC lifted its stake in shares of Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after buying an additional 30,000 shares in the last quarter. 34.63% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.60% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on the stock. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies set a $3.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Monday, October 23rd. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has a consensus rating of “Buy” and an average price target of $3.84.

Antares Pharma, Inc. (ATRS) opened at $2.22 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34. Antares Pharma, Inc. has a 52 week low of $1.58 and a 52 week high of $4.09.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma’s quarterly revenue was up 11.9% on a year-over-year basis. equities analysts expect that Antares Pharma, Inc. will post -0.11 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/antares-pharma-inc-atrs-holdings-boosted-by-wells-fargo-company-mn/1797789.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.